Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab in Persistent or Recurrent Cervical Squamous Cell Carcinoma
NCT00025233Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2002
- Primary completion
- Jul 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in cervical squamous cell carcinoma (CSCC), sponsored by National Cancer Institute. Started Apr 2002; status: completed.
02
Drugs
bevacizumab
03
Conditions
cervical squamous cell carcinoma (CSCC)
Beyond the preview
Go deeper on NCT00025233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00025233.